McMasterLogo_New-2017-300x165
Back
Evidence Summary

What is an Evidence Summary?

Key messages from scientific research that's ready to be acted on

Got It, Hide this
  • Rating:

Screening is not recommended for women at average risk for ovarian cancer who do not have symptoms

Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319:595-606.

Grossman DC, Curry SJ, Owens DK, et al. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;319:588-94.

Review and guideline questions

In women at average risk who do not have symptoms, what are the benefits and harms of screening tests for ovarian cancer?

Background

Ovarian cancer is a common cause of cancer death in women over 45 years of age. Women with early-stage ovarian cancer may not have any symptoms. This is a serious problem because by the time symptoms develop (e.g., persistent abdominal pain or pressure, bloating, constipation, urinary symptoms, back pain, or fatigue), the cancer has often spread beyond the ovaries. Early detection of ovarian cancer with an ultrasound or blood test may improve success of treatments. However, some women who do not have ovarian cancer will have a positive screening test result and may have surgery when they don’t need it. This exposes them to potentially serious complications without any benefit.

How the review was done

Researchers in the USA did a systematic review of studies available up to November 2017. They found 4 randomized controlled trials of 293,587 women who were 45 years or older.

The key features of the RCTs were:

  • participants were women who did not have any symptoms and did not have a family history of ovarian cancer or breast cancer or other high-risk hereditary cancer syndromes before screening; and
  • screening with transvaginal ultrasound and/or a blood test was compared with no screening.

What the researchers found

Screening for ovarian cancer did not reduce deaths due to ovarian cancer compared with no screening.

After 2 to 11 years of annual screening, up to 44% of women had at least 1 false-positive test result.

Up to 3% of women with a false-positive test result had unnecessary surgery.

Interpretation

Why does screening for ovarian cancer not work?

There are two reasons: (1) early-stage ovarian cancer usually does not cause symptoms, so women don’t know they have a problem; and (2) the tests we currently have are not very good at detecting early-stage ovarian cancer (i.e., they often indicate cancer is present when it is not). In late-stage ovarian cancer, the symptoms—persistent abdominal pain or pressure, bloating, constipation, urinary symptoms, back pain, or fatigue—are nonspecific. This means they are more common in women who do not have ovarian cancer. For this reason, doctors may miss the diagnosis.

Recommendation

In women at average risk for ovarian cancer (no family history of ovarian or breast cancer) who  do not have symptoms, screening is not recommended.

Ovarian cancer screening vs no screening in women at average risk who do not have  symptoms

Outcomes

Number of trials (number of women)

Effects of screening

Death

3 trials (293,038 women)

Death due to ovarian cancer was not reduced in women screened each year at 3 to 12 years of follow-up.

False-positive test results

3 trials (293,038 women)

Up to 44% of women screened each year for up to 11 years had at least 1 positive test but did not have ovarian cancer.

Surgery

3 trials (293,038 women)

Between 1% and 3% of women who had a positive screening result had surgery but no cancer was found.

 




Glossary

False-positive
A test result that suggests the presence of a disease which turns out not to be there.
Randomized controlled trials
Studies where people are assigned to one of the treatments purely by chance.
Systematic review
A comprehensive evaluation of the available research evidence on a particular topic.

Related Web Resources

  • Healthy Bones: A Decision Aid for Women After Menopause

    OHRI
    This patient decision aid helps women who have gone through menopause and may have osteoporosis decide on methods to keep your bones healthy. It facilitates the process by outlining and comparing the choices such as medicine, menopausal hormone therapy (MHT), and exercise.
  • Breast cancer: Risks and benefits, age 50-69

    Canadian Task Force on Preventive Health Care
    Your risk of dying from breast cancer is slightly reduced if you have regular screening. However, regular screening increases your chance of a false positive result, a biopsy and having part or all of a breast removed unnecessarily.
  • Breast cancer: Patient algorithm

    Canadian Task Force on Preventive Health Care
    The Canadian Task Force on Preventive Health Care recommends women between 50 and 74 years old who are not at high risk get screened for breast cancer every 2 to 3 years. Talk to your doctor about screening options if you are at high risk or over 74 years old.
DISCLAIMER These summaries are provided for informational purposes only. They are not a substitute for advice from your own health care professional. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the McMaster Optimal Aging Portal (info@mcmasteroptimalaging.org).

Register for free access to all Professional content

Register